# Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

> **NCT00685854** · PHASE1 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 5 (actual)

## Conditions studied

- Macular Telangiectasia

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00685854
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-21
- **Primary completion:** 2011-03-24
- **Final completion:** 2011-03-24
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00685854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00685854, "Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00685854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*